Entropy Technologies LP Sells 164,892 Shares of Bristol Myers Squibb Company $BMY

Entropy Technologies LP decreased its holdings in Bristol Myers Squibb Company (NYSE:BMY) by 62.7% in the first quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 98,252 shares of the biopharmaceutical company’s stock after selling 164,892 shares during the quarter. Entropy Technologies LP’s holdings in Bristol Myers Squibb were worth $5,959,000 at the end of the most recent quarter.

A number of other institutional investors have also recently made changes to their positions in BMY. Swiss RE Ltd. bought a new stake in Bristol Myers Squibb in the 4th quarter worth approximately $25,000. Darwin Wealth Management LLC bought a new stake in shares of Bristol Myers Squibb in the second quarter worth $25,000. Physician Wealth Advisors Inc. increased its position in Bristol Myers Squibb by 73.5% during the fourth quarter. Physician Wealth Advisors Inc. now owns 477 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 202 shares during the last quarter. Bayban purchased a new position in Bristol Myers Squibb in the fourth quarter worth about $31,000. Finally, EQ Wealth Advisors LLC bought a new stake in shares of Bristol Myers Squibb during the 4th quarter valued at about $32,000. Hedge funds and other institutional investors own 76.41% of the company’s stock.

Bristol Myers Squibb Trading Up 0.9%

Shares of BMY stock opened at $62.05 on Friday. The stock has a fifty day simple moving average of $57.49 and a two-hundred day simple moving average of $58.03. Bristol Myers Squibb Company has a 52-week low of $42.52 and a 52-week high of $62.89. The firm has a market capitalization of $126.70 billion, a PE ratio of 17.43, a PEG ratio of 0.18 and a beta of 0.23. The company has a debt-to-equity ratio of 2.10, a quick ratio of 1.28 and a current ratio of 1.42.

Bristol Myers Squibb (NYSE:BMY) last released its earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.58 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.42 by $0.16. Bristol Myers Squibb had a return on equity of 64.87% and a net margin of 15.01%.The firm had revenue of $11.49 billion during the quarter, compared to analysts’ expectations of $10.93 billion. During the same quarter last year, the business posted $1.80 earnings per share. The firm’s revenue was up 2.6% on a year-over-year basis. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. On average, analysts predict that Bristol Myers Squibb Company will post 6.34 EPS for the current fiscal year.

Bristol Myers Squibb Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Monday, August 3rd. Investors of record on Thursday, July 2nd will be given a dividend of $0.63 per share. The ex-dividend date is Thursday, July 2nd. This represents a $2.52 dividend on an annualized basis and a dividend yield of 4.1%. Bristol Myers Squibb’s dividend payout ratio is currently 70.79%.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on BMY shares. Bank of America lowered their price objective on shares of Bristol Myers Squibb from $67.00 to $66.00 and set a “buy” rating on the stock in a research note on Friday, July 10th. UBS Group reiterated a “buy” rating on shares of Bristol Myers Squibb in a research report on Thursday, May 28th. Wall Street Zen upgraded shares of Bristol Myers Squibb from a “buy” rating to a “strong-buy” rating in a research note on Saturday, June 27th. Citigroup reaffirmed a “neutral” rating on shares of Bristol Myers Squibb in a report on Friday, May 1st. Finally, Guggenheim reissued a “buy” rating and set a $72.00 price target on shares of Bristol Myers Squibb in a report on Wednesday, April 8th. Eight research analysts have rated the stock with a Buy rating, ten have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $61.25.

Bristol Myers Squibb News Summary

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Bristol Myers Squibb announced progress on a new lung cancer combination therapy, advancing the program into Phase 2. That suggests continued pipeline momentum and gives investors another potential long-term growth catalyst. Article Title
• Positive Sentiment: The company also expanded its pipeline with a first-in-human trial for BMS-986533, reinforcing the view that Bristol Myers is still investing in new drug candidates beyond its current blockbuster portfolio. Article Title
• Neutral Sentiment: Multiple previews ahead of Bristol Myers Squibb’s upcoming earnings report point to Wall Street expecting earnings growth and a possible beat, which may be supporting shares ahead of the release. Article Title
• Neutral Sentiment: An analyst note on Bristol Myers Squibb was published, but the headline indicates general commentary rather than a major new thesis change, so the market impact appears limited. Article Title
• Negative Sentiment: Broader healthcare commentary flagged some names to avoid, but Bristol Myers Squibb was not singled out; still, it reflects a mixed sentiment backdrop for the sector rather than a company-specific setback. Article Title

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late?stage pipeline reflect a strong emphasis on cancer and immune?mediated conditions.